Company / R&D Expense
Apellis Pharmaceuticals, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$295.9M
FY2025
5-year range
$295.9M / $387.2M
FY2021-FY2025
Trend
-9.7%
vs FY2024
Sector context
#62 of 210
Health Care
What the data says
At $296M, Apellis Pharmaceuticals, Inc.'s r&d expense ranks #62 of 210 in the Health Care sector. R&D Expense has declined for 3 consecutive years, from $387M in FY2022 to $296M in FY2025.
Based on SEC 10-K filings.
$296M in FY2025 with a 5-year CAGR of -0.3%.
Declined from $354M to $296M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -8.6%
- 5-Year CAGR
- -0.3%
- 10-Year CAGR
- -
Sector benchmark
#62 of 210 in Health CareTop 30% of 210This company $295.9M Sector average $644.1M
▼
-54.1% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s r&d expense has declined for 3 consecutive years.
- 5-year CAGR of -0.3%, indicating a declining trend.
- In FY2025, r&d expense decreased 9.7% year-over-year.
- Ranks #62 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $295.9M | -9.7% |
| FY2024 | $327.6M | -7.6% |
| FY2023 | $354.4M | -8.5% |
| FY2022 | $387.2M | +12.0% |
| FY2021 | $345.9M | +15.3% |
| FY2020 | $299.9M | +35.7% |
| FY2019 | $221.0M | +109.9% |
| FY2018 | $105.3M | +161.2% |
| FY2017 | $40.3M | +75.4% |
| FY2016 | $23.0M | +67.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026